Clinical Trial Update: Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

View source ↗

Summary

This clinical trial update describes a study investigating circulating tumor DNA as a prognostic factor in patients with resectable Stage IIIA non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fundación GECP | Conditions: Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment | Status: ACTIVE_NOT_RECRUITING